Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.
Journal
The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
04
01
2022
revised:
18
01
2022
accepted:
20
01
2022
pubmed:
7
2
2022
medline:
31
3
2022
entrez:
6
2
2022
Statut:
ppublish
Résumé
Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases in many countries. Because Omicron was recognized recently, many knowledge gaps exist about its epidemiology, clinical severity, and disease course. A genome sequencing study of SARS-CoV-2 in the Houston Methodist health care system identified 4468 symptomatic patients with infections caused by Omicron from late November 2021 through January 5, 2022. Omicron rapidly increased in only 3 weeks to cause 90% of all new COVID-19 cases, and at the end of the study period caused 98% of new cases. Compared with patients infected with either Alpha or Delta variants in our health care system, Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with on average decreased disease severity. Two patients with Omicron stealth sublineage BA.2 also were identified. The data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron variant in metropolitan Houston, Texas, and address the lack of information about disease character among US patients.
Identifiants
pubmed: 35123975
pii: S0002-9440(22)00044-X
doi: 10.1016/j.ajpath.2022.01.007
pmc: PMC8812084
pii:
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
642-652Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00076
Pays : United States
Informations de copyright
Copyright © 2022 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Références
Lancet Infect Dis. 2022 Mar 17;:
pubmed: 35305699
Euro Surveill. 2022 Jan;27(4):
pubmed: 35086609
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Am J Pathol. 2022 Feb;192(2):320-331
pubmed: 34774517
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Nat Commun. 2022 Feb 9;13(1):852
pubmed: 35140233
Clin Infect Dis. 2022 Feb 16;:
pubmed: 35171987
Am J Pathol. 2021 Oct;191(10):1754-1773
pubmed: 34303698
Cell Discov. 2022 Jan 17;8(1):4
pubmed: 35034952
Cell Rep Med. 2022 Jan 24;3(2):100529
pubmed: 35233550
Am J Pathol. 2022 Apr;192(4):642-652
pubmed: 35123975
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
mBio. 2020 Oct 30;11(6):
pubmed: 33127862
Science. 2022 Mar 25;375(6587):1406-1411
pubmed: 35133177
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Am J Pathol. 2021 Jun;191(6):983-992
pubmed: 33741335
NPJ Vaccines. 2022 Mar 8;7(1):35
pubmed: 35260578
Med (N Y). 2022 Mar 17;:
pubmed: 35313451
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Eur J Immunol. 2022 Mar 21;:
pubmed: 35312186
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
N Engl J Med. 2022 Mar 2;:
pubmed: 35249272
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Antiviral Res. 2022 Feb;198:105253
pubmed: 35066015